# CanSino Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cansino-biologics

- Industry: Pharmaceuticals
- Headquarters: Tianjin, China
- Website: www.cansinotech.com
- Total disclosed funding: $136M
- Latest round: Series E (Apr 18, 2017)
- Investors on record: 6

## About

Founded in 2009 and based in Tianjin, China, CanSino Biologics Inc. operates as a biotechnology company that provides solutions to prevent communicable and infectious diseases. In 2012, the company completed the construction of a pilot plant designed to meet GMP standards. In 2018, it completed construction of a commercial production center. In 2019, the company was listed on the Hong Kong Stock Exchange. Its stock code is 6185. In 2020, CanSino Biologics Inc. was listed on the Shanghai Stock Exchange. Its stock code is 688185. The firm has vaccine industry bases in Tianjin and Shanghai, with a construction area of over 200,000 square meters.

The company's main products include the new coronavirus vaccine (type 5 adenovirus vector) Keweisha®, the new crown vaccine Kewisha® Wuyou®, the quadrivalent meningococcal conjugate vaccine ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) Mann Haixin® and bivalent meningococcal conjugate vaccine group A and group C meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Minasi®, etc. Its products are used in diseases such as COVID-19, Ebola virus disease, tuberculosis, meningitis, and diphtheria.

## Funding rounds

- Series E, Apr 18, 2017, $65M — Qiming Venture Partners, Lilly Asia Ventures, CITIC Goldstone Fund Management, Fortune Capital, CS Capital, Gopher Asset Management
- Series D, Apr 21, 2016, $31M — Qiming Venture Partners
- Series C, Nov 3, 2015, $30M — Qiming Venture Partners, Lilly Asia Ventures
- Series A, Sep 6, 2013, $10M — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series C, Series E
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C, Series D, Series E
- CITIC Goldstone Fund Management (https://capitalatlas.ai/funds/citic-goldstone-fund-management) — Series E
- Fortune Capital — Series E
- CS Capital — Series E
- Gopher Asset Management (https://capitalatlas.ai/funds/gopher-asset-management) — Series E